Skip to main content
ADIL
NASDAQ Life Sciences

AD04 制造成功为第三期临床批次铺平了道路

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$1.587
Mkt Cap
$2.267M
52W Low
$1.54
52W High
$30.25
Market data snapshot near publication time

summarizeSummary

Adial Pharmaceuticals 宣布其主要药物候选物 AD04 的示范批生产成功完成。这一里程碑证实制造工艺符合所有预先指定的测试规格和监管要求，从而使得能够生产用于计划的第三期试验的临床和注册批次。这一技术成就是 Adial 的一个关键去风险步骤，尤其是在公司最近的 10-K 文件中强调了对其继续经营的重大疑虑的背景下。推进 AD04 对于公司的未来至关重要，这一制造成功消除了一个重大障碍，允许向关键的第三期临床计划进展。投资者现在将关注第三期试验启动和与 FDA 进一步的监管讨论的更新。

在该公告发布时，ADIL的交易价格为$1.59，交易所为NASDAQ，所属行业为Life Sciences，市值约为$226.7万。 52周交易区间为$1.54至$30.25。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ADIL - Latest Insights

ADIL
Apr 29, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
8
Adial Files New Patent Application for AD04, Targeting Market Exclusivity Through 2045
Sentiment: Positive
View Wiseek Article
ADIL
Apr 22, 2026, 9:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
AD04 Manufacturing Success Paves Way for Phase 3 Clinical Batches
Sentiment: Positive
View Wiseek Article
ADIL
Apr 09, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Grants Significant Equity Awards to Executives and Directors Amidst Going Concern Doubts
Sentiment: Neutral
View Wiseek Article
ADIL
Mar 24, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Bipartisan Bill to Expand Veteran Access to AUD Therapies Introduced, Benefiting Adial's AD04
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Details Positive AD04 Regulatory Progress, Streamlined Phase 3 Path, and 2025 Financials
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Adial Pharmaceuticals Advances AD04 to Phase 3, Citing FDA Alignment and Potential for Single Pivotal Study
Sentiment: Positive
View Wiseek Article
ADIL
Mar 05, 2026, 5:05 PM EST
Source: Wiseek News
Importance Score:
8
Adial Pharma's Cash Runway into H2 2026 Raises Funding Concerns for Pivotal Trials
Sentiment: Negative
View Wiseek Article
ADIL
Mar 05, 2026, 5:03 PM EST
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Substantial Doubt on Going Concern, New Nasdaq Delisting Threat Looms
Sentiment: Negative
View Wiseek Article
ADIL
Mar 03, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Secures Exclusive European Partnership Framework for AD04, Valued at Up to $60M
Sentiment: Neutral
View Wiseek Article
ADIL
Feb 24, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Regains Nasdaq Compliance Following Reverse Stock Split
Sentiment: Positive
View Wiseek Article